Epistem Hoping to Apply 'Plucked Hair' Biomarker Approach to Cancer Drug Studies | GenomeWeb
NEW YORK (GenomeWeb News) – British biotech firm Epistem has completed a preliminary study of its plucked hair biomarker technology with AstraZeneca, the company announced today.
The minimally invasive hair biomarker system makes it possible to retrieve RNA from the base of a single, plucked human hair, facilitating gene expression measurements.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.